Mayne Pharma Engages in Legal Battle with Cosette Over Scheme Termination

Mayne Pharma Group ( (AU:MYX) ) has provided an update.

Mayne Pharma Group Limited is currently engaged in litigation with Cosette Pharmaceuticals, Inc. regarding the termination of a scheme implementation deed. The dispute, which is set for a court hearing on 9 September 2025, involves Cosette’s claims of a valid termination and allegations of misleading conduct by Mayne Pharma. Mayne Pharma denies these claims and intends to defend its position while continuing to recommend shareholders vote in favor of the Scheme Resolution at the upcoming meeting.

The most recent analyst rating on (AU:MYX) stock is a Buy with a A$7.09 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.

More about Mayne Pharma Group

Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercializing novel pharmaceuticals, offering patients better, safe, and more accessible medicines. It is a leader in dermatology and women’s health in the United States and provides contract development and manufacturing services globally. With a 40-year track record, Mayne Pharma has been successful in developing and commercializing new oral drug delivery systems.

YTD Price Performance: 4.63%

Average Trading Volume: 969,202

Technical Sentiment Signal: Sell

Current Market Cap: A$422.5M

For detailed information about MYX stock, go to TipRanks’ Stock Analysis page.